Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 22

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 22
---

Approval of Proposal No. 1 requires the affirmative vote of a majority of the outstanding shares of Common Stock entitled to vote on the proposal. Abstentions will have the effect of a vote “AGAINST” this proposal.

#### Board Recommendation
**OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THIS PROPOSAL NO. 1 TO APPROVE THE REVERSE STOCK SPLIT.**

<div align='center'>12</div>

TABLE OF CONTENTS

PROPOSAL 2: THE ISSUANCE PROPOSAL On March 4, 2025, the Company consummated the previously announced private placement (the “Private Placement”) pursuant to that certain securities purchase agreement (“Purchase Agreement”) with accredited investors, including certain existing stockholders of the Company (collectively, the “Purchasers”). The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 28,042,140 shares of the Company’s Common Stock, or, at the election of each Purchaser, prefunded warrants to purchase Common Stock (the “Prefunded Warrants”), exercisable immediately at an exercise price of $0.001 per share, with each share of Common Stock or Prefunded Warrant accompanied by (i) one Series A common warrant (the “Series A Warrants”) to purchase one share of Common Stock (the “Series A Warrant Shares”), and (ii) one Series B common warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Warrants”) to purchase one share of Common Stock (the “Series B Warrant Shares” and together with the Series A Warrant Shares, the “Warrant Shares”). The combined purchase price of $0.66 for each share of Common Stock or $0.659 for each Prefunded Warrant in the Private Placement, together with one accompanying Series A Warrant and one accompanying Series B Warrant, represented the applicable “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d). The initial exercise price of each Series A Warrant is $1.32 per share of Common Stock. The initial exercise price of each Series B Warrant is $1.98 per share of Common Stock. The Series A Warrants and Series B Warrants are subject to a “reset provision,” pursuant to which the exercise price of the Series A Warrants and Series B Warrants may be reduced to a price not less than $0.132 (